Estimating (stage-)sojourn time for multiple cancer-sites: literature review and structured elicitation of expert beliefs
Preprint
Abstract
Preclinical cancer sojourn time—defined here as the duration a cancer is undetected but detectable—is important for understanding disease progression and evaluating screening policies. This study aims to robustly characterise empirical evidence and existing knowledge over mean sojourn times across 21 stageable tumour sites, including stage-specific preclinical cancer sojourn times and the sojourn time of circulating tumour DNA (ctDNA)-positive cancers. We updated an existing literature review through to February 2025 to extract population-level empirical sojourn time estimates derived from mathematical models of primary screening data. To synthesise this heterogeneous literature, quantify uncertainty, and obtain estimates for cancer-sites lacking empirical evidence, we conducted a formal Structured Expert Elicitation involving 15 clinical experts. The elicitation was grounded on the literature review results, supplemented by an evidence dossier that included survival data and outcomes from relevant ctDNA cancer studies. The literature review revealed heterogeneity in existing literature, which focused on a small subset of screened cancers (e.g., breast, cervical, colorectal). The elicitation successfully generated comprehensive probability distributions of overall mean sojourn times for all 21 cancer-sites (representing the site of tumour origin), as well as stage-specific sojourn times and overall sojourn times for ctDNA-positive cancers across 14 cancer-sites. This study used robust methodology to quantitatively describe existing evidence and experts’ beliefs on the sojourn time of multiple cancer-sites, also describing uncertainty. Such estimates are important for future evaluations of the clinical impact, potential for overdiagnosis and subsequent cost-effectiveness of emerging screening technologies, including multi-cancer detection tests.Keywords
This publication has 24 references indexed in Scilit:
- Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study‐3 and Circulating Cell‐Free Genome Atlas Substudy 3Cancer, 2026
- Modelled mortality benefits of multi-cancer early detection screening in EnglandBritish Journal of Cancer, 2023
- The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USAPharmacoEconomics, 2022
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation setAnnals of Oncology, 2021
- Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection TestCancer Epidemiology, Biomarkers & Prevention, 2021
- Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic EvaluationsPharmacoEconomics, 2016
- Uncertain Judgements: Eliciting Experts' Probabilities2006
- MLE and Bayesian Inference of Age‐Dependent Sensitivity and Transition Probability in Periodic ScreeningBiometrics, 2005
- Screening, Sojourn Time2005
- Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn timeInternational Journal of Cancer, 1997